Bristol-Myers Squibb Company (BMY) Rating Reiterated by BMO Capital Markets
BMO Capital Markets reissued their sell rating on shares of Bristol-Myers Squibb Company (NYSE:BMY) in a research report report published on Monday. The brokerage currently has a $49.00 price objective on the biopharmaceutical company’s stock.
Other equities analysts have also issued reports about the stock. Credit Suisse Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the company a hold rating in a report on Wednesday, August 16th. Leerink Swann cut their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an outperform rating for the company in a report on Friday, July 28th. Goldman Sachs Group, Inc. (The) reaffirmed a buy rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr raised shares of Bristol-Myers Squibb from a buy rating to a strong-buy rating and set a $64.33 target price for the company in a report on Wednesday, July 26th. Finally, Cowen and Company set a $65.00 target price on shares of Bristol-Myers Squibb and gave the company a hold rating in a report on Monday, August 14th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $62.54.
Shares of Bristol-Myers Squibb (BMY) opened at 62.84 on Monday. The firm’s 50-day moving average is $57.32 and its 200-day moving average is $55.65. The stock has a market capitalization of $103.05 billion, a PE ratio of 22.95 and a beta of 1.18. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $63.47.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the previous year, the business posted $0.69 EPS. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, analysts expect that Bristol-Myers Squibb will post $2.98 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) Rating Reiterated by BMO Capital Markets” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/08/bristol-myers-squibb-company-bmy-rating-reiterated-by-bmo-capital-markets.html.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.23% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in BMY. Verus Financial Partners Inc. purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth $206,000. Stokes & Hubbell Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 1.6% during the first quarter. Stokes & Hubbell Capital Management LLC now owns 13,300 shares of the biopharmaceutical company’s stock worth $723,000 after buying an additional 206 shares in the last quarter. Prentiss Smith & Co. Inc. grew its holdings in shares of Bristol-Myers Squibb by 61.8% during the first quarter. Prentiss Smith & Co. Inc. now owns 2,333 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 891 shares in the last quarter. Alpha Windward LLC grew its holdings in shares of Bristol-Myers Squibb by 0.9% during the first quarter. Alpha Windward LLC now owns 5,427 shares of the biopharmaceutical company’s stock worth $295,000 after buying an additional 51 shares in the last quarter. Finally, Prospera Financial Services Inc grew its holdings in shares of Bristol-Myers Squibb by 32.3% during the first quarter. Prospera Financial Services Inc now owns 65,532 shares of the biopharmaceutical company’s stock worth $3,527,000 after buying an additional 15,991 shares in the last quarter. 68.80% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.